BACK in 2019 at a US industry conference while discussing cannabis business models a top executive from JP Morgan said ‘Gap do not grow their own cotton’.
That makes sense for that industry but as we are in the cannabis space – not retail clothing – we need a different approach.
For the last four years I have worked at the very cutting edge of a cannabis cultivation business in La Jagua del Ibirico, a stunning place literally in the middle of nowhere in Colombia.
And, I can confirm from that first-hand experience that growing cannabis is indeed, very different to growing cotton!
‘Unmitigated Disaster’
The way cannabis develops will vary from country to country, location to location, strain to strain and whether it’s grown indoors, outdoors in the ground, or hydroponically.
So cannabis companies should not be looking to the likes of Gap for inspiration – the business model the industry should focus on is seed-to-sale control – vertical integration.
This starts with cultivation, then extraction, leading to the creation of an API, and on to the next step of manufacturing, then distribution.
There have been numerous examples of the North American industry forerunners identifying this as their preferred route.
But, to date, with a few exceptions, it has been nothing short of an unmitigated disaster.
We need to avoid the situation where gung-ho, highly-paid executives let their shareholders down by wasting millions of dollars in random buying sprees, without adequate due diligence and a long-term strategy.
Effectively, what we have witnessed is some businesses playing monopoly with shareholders money in what is akin to criminal behaviour.
There has to be a better way for the European industry to proceed and to my mind this could be achieved by like-minded individuals establishing solid working relationships across the supply chain with a view to eventual amalgamation.
Cannabis Medicines And CBD
As I have already indicated growing cannabis and then creating cannabis medicines from the plants can be quite a challenge.
The way all the cannabinoids, flavonoids and terpenes interact are key to understanding what will work best for what medical condition and this can only be done through extensive research.
Channelling medical cannabis along this route means we have to overcome more stringent entry barriers for our end products.
However, I would argue this is not necessarily the case in the CBD space. On the well-being side, with the novel food situation, then basically everybody’s product is the same.
I’m sure there are company’s out there that won’t like me saying this but other than all the other ingredients – the flavours, the smells, the other compounds and the creams and carriers, for example – the cannabis element is 99% exactly the same. It’s all CBD isolate.
Collaboration Is Key
One of the challenges for European-domiciled businesses is that there are different rules and regulations for each country.
By working as a team towards the same common goal there is the opportunity to tap into each party’s expertise without the need to spend lots of money owning everything, and expanding too quickly with runaway costs.
Industry partners needs to learn to work together so that each element is responsible for their part, then, as we grow and the revenue flows from each vertical we can then look at how each element could potentially merge to become one.
This can only really happen when each vertical is profitable and will avoid the situation we have just described where there’s a lot of money being spent sporadically with no profits being made.
You can’t buy your way out of problems – what you’ve got to do is work hard to create a solid foundation, move on to the next piece, build it up, and so on.
Once the revenues start to flow then that is the time to look for further consolidation and collaboration through buy-outs or mergers.
The only way this industry is going to grow is solid collaboration. By solid collaboration I mean that elements work together cohesively as a team; as a unit moving towards the same common goal, one that creates real solid businesses based on solid standards and foundations.
Carl Haffner is a Co-Founder of a vertically-integrated cannabis business which supplies all sectors from the medicinal to wellness and cosmeceutical.
Carl has now set up his own Cannabis Consultancy to support brands though to growers and anyone involved in the ever-shifting industry.
‘Collaborative Vertical Integration Has To Be The Way Forward For the European Cannabis Industry’
BACK in 2019 at a US industry conference while discussing cannabis business models a top executive from JP Morgan said ‘Gap do not grow their own cotton’.
That makes sense for that industry but as we are in the cannabis space – not retail clothing – we need a different approach.
For the last four years I have worked at the very cutting edge of a cannabis cultivation business in La Jagua del Ibirico, a stunning place literally in the middle of nowhere in Colombia.
And, I can confirm from that first-hand experience that growing cannabis is indeed, very different to growing cotton!
‘Unmitigated Disaster’
The way cannabis develops will vary from country to country, location to location, strain to strain and whether it’s grown indoors, outdoors in the ground, or hydroponically.
So cannabis companies should not be looking to the likes of Gap for inspiration – the business model the industry should focus on is seed-to-sale control – vertical integration.
This starts with cultivation, then extraction, leading to the creation of an API, and on to the next step of manufacturing, then distribution.
There have been numerous examples of the North American industry forerunners identifying this as their preferred route.
But, to date, with a few exceptions, it has been nothing short of an unmitigated disaster.
We need to avoid the situation where gung-ho, highly-paid executives let their shareholders down by wasting millions of dollars in random buying sprees, without adequate due diligence and a long-term strategy.
Effectively, what we have witnessed is some businesses playing monopoly with shareholders money in what is akin to criminal behaviour.
There has to be a better way for the European industry to proceed and to my mind this could be achieved by like-minded individuals establishing solid working relationships across the supply chain with a view to eventual amalgamation.
Cannabis Medicines And CBD
As I have already indicated growing cannabis and then creating cannabis medicines from the plants can be quite a challenge.
The way all the cannabinoids, flavonoids and terpenes interact are key to understanding what will work best for what medical condition and this can only be done through extensive research.
Channelling medical cannabis along this route means we have to overcome more stringent entry barriers for our end products.
However, I would argue this is not necessarily the case in the CBD space. On the well-being side, with the novel food situation, then basically everybody’s product is the same.
I’m sure there are company’s out there that won’t like me saying this but other than all the other ingredients – the flavours, the smells, the other compounds and the creams and carriers, for example – the cannabis element is 99% exactly the same. It’s all CBD isolate.
Collaboration Is Key
One of the challenges for European-domiciled businesses is that there are different rules and regulations for each country.
By working as a team towards the same common goal there is the opportunity to tap into each party’s expertise without the need to spend lots of money owning everything, and expanding too quickly with runaway costs.
Industry partners needs to learn to work together so that each element is responsible for their part, then, as we grow and the revenue flows from each vertical we can then look at how each element could potentially merge to become one.
This can only really happen when each vertical is profitable and will avoid the situation we have just described where there’s a lot of money being spent sporadically with no profits being made.
You can’t buy your way out of problems – what you’ve got to do is work hard to create a solid foundation, move on to the next piece, build it up, and so on.
Once the revenues start to flow then that is the time to look for further consolidation and collaboration through buy-outs or mergers.
The only way this industry is going to grow is solid collaboration. By solid collaboration I mean that elements work together cohesively as a team; as a unit moving towards the same common goal, one that creates real solid businesses based on solid standards and foundations.
Carl Haffner is a Co-Founder of a vertically-integrated cannabis business which supplies all sectors from the medicinal to wellness and cosmeceutical.
Carl has now set up his own Cannabis Consultancy to support brands though to growers and anyone involved in the ever-shifting industry.
Cannabis consulting firm aims to bring more business to European market
Next PostWho’ll be first to legalize adult-use? Germany or the US?
BusinessCann
Related Posts
Related Posts
Cannabis Rescheduling: DEA’s Decision Marks a New Era for the Industry
The US Drug Enforcement Administration (DEA) is set to approve the rescheduling of cannabis in a move set to have...
Germany’s ‘Pillar 2’ Is Already Being Worked On and Could Be Here Far Sooner Than Expected
Germany’s highly anticipated ‘Pillar 2’, which would seek to implement a Switzerland-style adult-use cannabis pilot project model, is now being...
Cannabis Rescheduling: Rumours Swirl on Imminent DEA Announcement as Legal Experts Expected to Weigh In
Germany’s Predicted Medical Cannabis Boom Is in Full Swing Following Passage of CanG
SAFER Banking Act Faces Last-Minute Opposition, Derails FAA Bill Plans
Hawaii Lawmakers Shoot Down Second Cannabis Reform Bill This Month
CONNECT
Related Posts
Related Posts
Cannabis Rescheduling: DEA’s Decision Marks a New Era for the Industry
The US Drug Enforcement Administration (DEA) is set to approve the rescheduling of cannabis in a move set to have...
Germany’s ‘Pillar 2’ Is Already Being Worked On and Could Be Here Far Sooner Than Expected
Germany’s highly anticipated ‘Pillar 2’, which would seek to implement a Switzerland-style adult-use cannabis pilot project model, is now being...
Cannabis Rescheduling: Rumours Swirl on Imminent DEA Announcement as Legal Experts Expected to Weigh In
Click here for the latest on the DEA's decision on cannabis rescheduling. Rumours are once again swirling that a decision...
Germany’s Predicted Medical Cannabis Boom Is in Full Swing Following Passage of CanG
It has been almost exactly a month since Germany’s CanG came into effect, making adult-use consumption and possession legal, within...
SAFER Banking Act Faces Last-Minute Opposition, Derails FAA Bill Plans
Hopes that the highly anticipated SAFER Banking Act could be attached to a ‘must pass’ bill were scuppered last week...
Recent Posts
Related Posts
Jersey Hemp Wins Watershed Legal Battle Against UK Home Office Which Threatened Entire CBD Industry
Jersey Hemp has won a watershed court battle against the UK Home Office, which has now admitted acting unlawfully in...
The Future of CBD in Japan: How Legal Reforms Will Shape the Market
Late last year, Japan made a major step towards cannabis reform after approving a bill to amend its 75-year-old Cannabis...
Chill Brands Stock Drops on News of Vaping Ban, Voyager Life Aquires CBD Retailer, & Pharma C Rebrands
Chill Brands Chill Brands has seen its stock price drop by more than 30% this week following news that...
Hemp Industry Calls on House Energy & Commerce Leaders to Hold Crucial Hearing on FDA Regulation
In a significant move to address the challenges faced by the U.S. hemp industry, 28 non-profit organizations – representing every...
Hemp Industry Calls on House Energy & Commerce Leaders to Hold Crucial Hearing on FDA Regulation
In a significant move to address the challenges faced by the U.S. hemp industry, 28 non-profit organizations – representing every...
Subscribe to our mailing list to receives daily updates!
We won’t spam you
Categories
Browse by Tags